Latest Breaking News On - Swiss group for clinical cancer research - Page 1 : comparemela.com

Intensity Therapeutics, Inc and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity s Lead Drug Candidate

Intensity Therapeutics, Inc and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity s Lead Drug Candidate
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesLewish benderJustin kulikJules abrahamIntensity therapeutics incCompany nasdaqEuropean unionSwiss cancer leagueSwiss group for clinical cancer researchPrnewswire intensity therapeutics incNational cancer instituteSwiss cancer research foundationCompetence centerSwiss groupClinical cancer researchCommon terminology criteria

Next-Gen PARP Inhibitor Shows Benefit in Breast Cancer Patients

Next-Gen PARP Inhibitor Shows Benefit in Breast Cancer Patients
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United statesHong kongUnited kingdomHaihe biopharmaBiocity biopharmaCalithera biosciencesTerremoto biosciencesBridgene biosciencesEli lillyTimothya yapRadiopharm theranosticsArtios pharmaDaiichi sankyoInstitut gustave roussyAduro biotech incAtrin pharmaceuticals

Perioperative Durvalumab Plus SOC Shows Promising EFS Results in Muscle-Invasive Urothelial Carcinoma

Treatment with neoadjuvant durvalumab plus gemcitabine and cisplatin followed by radical surgery and adjuvant durvalumab for patients with muscle-invasive urothelial carcinoma resulted in 2-year event-free survival rates that met the primary end point of the phase 2 SAKK 06/17 trial.

Swiss group for clinical cancer researchClinical oncologySwiss groupClinical cancer researchChronic kidney disease epidemiology collaborationNeoadjuvant durvalumabGemcitabine and cisplatinMuscle invasive urothelial carcinomaPhase 2 sakk 06 17 trial nct03406650

A young Geneva researcher wins one million Swiss Francs to conduct a clinical study on lymphoma

A young researcher from the Geneva University Hospital (HUG) and the University of Geneva (UNIGE), Dr Noémie Lang, wins the prestigious Swiss Group fo..

University of genevaTranslational research in oncoTrial network awardGeneva university hospitalWorld health organizationDepartment of medicineOncology departmentSwiss group for clinical cancer researchSwiss groupClinical cancer researchTranslational research

Major grant from the Swiss Group for Clinical Cancer Research for Noémie Lang - Faculté de médecine

Major grant from the Swiss Group for Clinical Cancer Research for Noémie Lang - Faculté de médecine
unige.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from unige.ch Daily Mail and Mail on Sunday newspapers.

World health organizationGeneva university hospitalUniversity of genevaNetwork trial awardTrial network awardSwiss group for clinical cancer researchTranslational research in oncoOncology departmentDepartment of medicineSwiss groupClinical cancer researchTranslational research